Table 4.
LOTa rules for SACTb and mortality information.
| Task | Data set A | Data set B |
|
||||||
| Task 10: number of patients initiating the target SACT by year and quarter | Figure 1A | Figure 1B |
|
||||||
| Task 11: completeness of LOT information, n (%)c |
|
||||||||
|
|
Patients with complete line number | 5594 (75.94) | 4589 (40.3) |
|
|||||
|
|
Patients with complete line name | 5594 (75.94) | N/Ad,e |
|
|||||
|
|
Patients with complete line start date | 5594 (75.94) | 4589 (40.3) |
|
|||||
|
|
Patients with complete line end date | 5594 (75.94) | N/Ae |
|
|||||
| Task 12: patients for whom the first LOT number after the advanced HNCf diagnosis date was not 1, n (%)c | 0 (0) | 434 (3.81) |
|
||||||
| Task 13: distribution of LOT number at target SACT initiation |
|
||||||||
|
|
Patients who received the target SACT, n | 1200 | 237 |
|
|||||
|
|
Line 1, n (%) | 481 (40.08) | 65 (27.43) |
|
|||||
|
|
Line 2, n (%) | 486 (40.5) | 92 (38.82) |
|
|||||
|
|
Line 3, n (%) | 161 (13.42) | 54 (22.78) |
|
|||||
|
|
Line 4, n (%) | 46 (3.83) | 16 (6.75) |
|
|||||
|
|
Line 5, n (%) | 13 (1.83) | 10 (4.22) |
|
|||||
|
|
Lines 6-10, n (%) | 13 (1.83) | 0 (0) |
|
|||||
| Task 14: use of target SACT in 1Lg before approval date |
|
||||||||
|
|
1L monotherapy |
|
|||||||
|
|
|
Patients who received target SACT, % (n/N) | 78.37 (377/481) | 67.69 (44/65) | |||||
|
|
|
First administration dateh in database | July 15, 2015 | November 10, 2014 | |||||
|
|
|
Cutoff date for the earliest 5% receipt | August 29, 2016 | February 4, 2016 | |||||
|
|
|
Cutoff date for the earliest 10% receipt | November 3, 2016 | September 23, 2016 | |||||
|
|
|
Cutoff date for the earliest 25% receipt | June 28, 2017 | April 27, 2017 | |||||
|
|
Approved 1L combination |
|
|||||||
|
|
|
Patients who received the target SACT in approved 1L combination, % (n/N) | 7.69 (37/481) | 6.15 (4/65) | |||||
|
|
|
First administration date in database | December 18, 2018 | July 1, 2019 | |||||
|
|
|
Cutoff date for the earliest 5% receipt | February 18, 2019 | N/Ai | |||||
|
|
|
Cutoff date for the earliest 10% receipt | April 2, 2019 | N/Ai | |||||
|
|
|
Cutoff date for the earliest 25% receipt | July 9, 2019 | N/Ai | |||||
| Task 15: patients with death record, n (%)c | 4695 (63.74) | 3531 (31) |
|
||||||
| Task 16: patients with multiple death records on different dates, n (%) | 0 (0) | N/Aj |
|
||||||
| Task 17: patients with clinical records showing health care activity after death date (n=4695), n (%) | 1497 (31.88) | N/Aj |
|
||||||
|
|
≥1 d after date of death | 1436 (30.59) | N/Aj |
|
|||||
|
|
≥3 d after date of death | 1290 (27.48) | N/Aj |
|
|||||
|
|
≥7 d after date of death | 1002 (21.34) | N/Aj |
|
|||||
|
|
≥30 d after date of death | 79 (1.68) | N/Aj |
|
|||||
a LOT: line of therapy.
bSACT: systemic anticancer therapy.
cTasks 11, 12, and 15 were applied to the full data sets, including 7366 and 11,386 patients in Data sets A and B, respectively.
dN/A: not applicable.
eLine name and line end date were not available in Data set B.
fHNC: head and neck cancer.
g1L: first line of therapy after the advanced HNC diagnosis date.
hDates are written as month/day/year.
iNot calculated as only 4 patients received the target SACT in a 1L combination LOT.
jOnly the year of death was available in Data set B.